China's Hybio Challenges Eli Lilly Patents With First Generic Filing for Blockbuster Weight-Loss Drug TirzepatideYicai·Jul 1 at 06:31 AM300199+6.78%LLY-4.55%
HYBIO plans to raise no more than 968 million yuan through a private placement for multiple projects and to supplement working capitalZhitong·Sep 25, 2025 at 07:01 AM300199+6.78%
The industrial hemp sector has undergone significant adjustments, and GETM has hit the daily limit downZhitong·Aug 21, 2025 at 08:51 PM603998-0.11%600232+1.76%
HYBIO released its performance for the first half of the year, turning a loss into a profit of 145 million yuanZhitong·Aug 21, 2025 at 05:54 AM300199+6.78%
HYBIO: Acetate Atosiban Injection has obtained marketing authorization in VietnamZhitong·Aug 21, 2025 at 03:58 AM300199+6.78%
HYBIO: Signed a series of commercialization agreements with Sanofi, with the weight loss drug expected to reach a peak annual sales of 30 million unitsZhitong·Aug 19, 2025 at 06:26 PM300199+6.78%
Weight loss drug concept stocks fluctuate and rise, HYBIO increases by over 10%Zhitong·Aug 17, 2025 at 08:39 PM300199+6.78%
The concept of innovative drugs is active again, Shen Lian Biomedical has achieved a two-day limit upZhitong·Aug 17, 2025 at 08:37 PM688336+4.32%688098+4.22%
The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin falling over 6%Zhitong·Aug 5, 2025 at 08:52 PM002275-0.38%300199+6.78%
HYBIO issued a profit warning, with a net profit attributable to the parent company of 142 million to 162 million yuan in the first half of the year, turning a loss into a profit year-on-yearZhitong·Jun 30, 2025 at 04:49 AM300199+6.78%
HYBIO: Acetate Degarelix raw material drug has been approved for listingZhitong·Jun 25, 2025 at 05:29 AM300199+6.78%
